Free Trial
NASDAQ:OMGA

Omega Therapeutics Q1 2024 Earnings Report

Omega Therapeutics logo
$0.12 -0.03 (-21.83%)
Closing price 02/24/2025
Extended Trading
$0.12 0.00 (0.00%)
As of 02/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omega Therapeutics EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.38
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Omega Therapeutics Revenue Results

Actual Revenue
$2.36 million
Expected Revenue
$0.93 million
Beat/Miss
Beat by +$1.43 million
YoY Revenue Growth
N/A

Omega Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Monday, May 6, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Omega Therapeutics' Q4 2024 earnings is scheduled for Friday, June 20, 2025

Omega Therapeutics Earnings Headlines

Omega Therapeutics Inc (OMGAQ)
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Omega Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Omega Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Omega Therapeutics and other key companies, straight to your email.

About Omega Therapeutics

Omega Therapeutics (NASDAQ:OMGA) operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

View Omega Therapeutics Profile

More Earnings Resources from MarketBeat